Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.61 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545446 | 0.90 | OPRM1 (0.75) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL4545444 | 0.86 | OPRM1 (0.80) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL6865494 | 0.83 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL6865490 | 0.83 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8208118 | 0.80 | OPRM1 (0.65) | OPRM1OPRK1OPRD1 | |
| SCHEMBL8208119 | 0.80 | OPRM1 (0.65) | OPRM1OPRK1OPRD1 | |
| SCHEMBL8206819 | 0.79 | OPRM1 (0.66) | OPRM1OPRK1OPRD1 | |
| SCHEMBL8206821 | 0.79 | OPRM1 (0.66) | OPRM1OPRK1OPRD1 | |
| SCHEMBL8207923 | 0.79 | OPRM1 (0.63) | OPRM1OPRK1OPRD1 | |
| SCHEMBL12030890 | 0.79 | OPRD1 (0.62) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.